Relief TherapeuticsSupporting patients through innovation and technology
GAEL HEDOU - Chief Executive Officer ad interim
Dr. Gaël Hédou was born in France in 1972. He graduated in Neuroscience from the University of Strasbourg (FR) in 1997. He then completed his PhD in Natural Sciences at the ETH in Zurich (CH) in the field of drug addiction. He pursued his academic research with a postdoc at the ETH studying brain plasticity and repair before joining the pharmaceutical industry. He started his industrial career at GlaxoSmithKline, Verona (IT) in 2004 were he led a laboratory supporting both preclinical and clinical projects in Psychiatric diseases. He joined Merck Serono KGaA in 2008 to participate in the implementation of the drug discovery and development strategy in Parkinson’s disease. Under his supervision, drug discovery projects became the basis for a spin off company of Merck Serono KGaA. Dr. Hedou has acquired expertise in the field of drug discovery and project management through different positions of increasing responsibility. He is one of the co-founder of Relief Therapeutics SA were he supported mainly the strategical positioning and fundraising campaign of the company as a managing partner and administrator.
TIM SNYDER - Chief Financial Officer
Timothy Snyder, a US citizen born in 1966, has been the Group CFO since April 2014. He graduated in 1988 with a degree in Business Administration from The Ohio State University (USA) and subsequently obtained certification as a CPA (Certified Public Accountant). Mr. Snyder spent the first nine years of his career with Deloitte then served as Finance Director and CFO at several international companies in the USA and Europe – primarily in the private equity sector. Mr. Snyder has consistently demonstrated strong leadership and technical skills, especially in the area of turn-arounds and restructurings. He also has extensive experience with post-merger integrations and the assimilation and stream-lining of financial processes
YVES SAGOT - Chief Scientific Officer
Dr Yves Sagot, born in 1964, is a French citizen. Yves received his PhD in Neurobiology at the University Paul Sabatier (Toulouse, France) for his work on factors regulating axonal regeneration. He did his postdoctoral studies at the University Medical Center (CMU, University of Geneva) on motoneuron diseases. In 1999 he joined Serono international SA, to work on neurodegenerative and neuroinflammatory diseases as group leader and technological platform leader. In 2001 he received the Serono CEO award for his team building spirit and accomplished work. He had the privilege to bring a biologics towards phase I for an autoimmune disease of the peripheral nervous system. Following Merck take-over in 2007, Dr Yves Sagot activities focused on therapeutic target validation for Alzheimer and Parkinson’s diseases, through internal and external partnerships with public or privates institutions. Pairs acknowledged his work through the Merck Serono Reward and Recognition award 2008 for innovation and target support. He is one of the founders of Relief Therapeutics SA acting as managing partner and CSO. In 2014, he completed his formation by obtaining a Certificate of Advance Studies in Management of Biotech, Medtech and Pharma Ventures at the EPFL (Swiss Federal Institute of Technology, Lausanne, Switzerland). Until recently, he maintained his consulting activities as expert on neurodegenerative diseases and target validation for private and public foundations.
MICHEL DREANO - Chief Business Officer
Dr Michel Dreano, born in 1957, is a French citizen. He got a PhD in Molecular Virology at the Institut Pasteur/University Paris VII and a PhD in Molecular and Cellular Biology at the University of Burgundi (France). He joined the Battelle Memorial Institute in Geneva in 1983 where he headed a group involved in the production of recombinant proteins. He moved to Serono International SA in 1989 where he operated as a drug developer and then as a project/alliance manager. In this context, he managed many strategic collaborations and partnerships with academic institutions, research contract organizations, biotechs or large pharmaceutical organizations. In 2007 after the acquisition of Serono International SA by Merck KGaA, Dr Michel Dreano pursued the management of international research projects and integrated the business development department. In 2012, Dr Michel Dreano created an independent consulting company specialized in the management of multidiplinary and cross-national R&D projects. He also participated in the creation of a not-for-profit Foundation, ReMedys, where he serves as an executive member of the Board of Directors. Finally, Dr Michel Dreano is one of the three founders of Relief Therapeutics SA. In the later company he was an active managing partner and operated as Chairman/President.
DORIAN BEVEC - Chief Development Officer
Dr. habil. Dorian Bevec, a German national, born in 1957 holds a Ph.D. (Dr. rer. nat.) from the Ludwig-Maximilians-University of Munich and a habilitation (Venia Docendi) from the University of Vienna. He is a co-founder of the former mondoBIOTECH. Prior to that, Dr. Bevec worked as Head of Molecular Biology and project team leader at the Sandoz Research Institute in Vienna for ten years and at Axxima AG in Martinsried for two years.